Hedi-Britt Klotškova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hedi-Britt Klotškova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Bas Oldenburg
Department of Gastroenterology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2 shared publications- Femke van Wijk
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
2 shared publications Fiona D. M. van Schaik
Department of Gastroenterology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2 shared publications- Karlijn P. M. Suijkerbuijk
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands
2 shared publications - M. Marlot van der Wal
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications - Mark Schuiveling
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands
2 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 49
Author Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
- 23 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 49
Open AccessAuthor Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
- Open Access
- 18 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 472
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
Background High-dose steroids constitute the cornerstone of first-line treatment for immune-related adverse events (irAEs) associated with immune checkpoint inhibitors, but compromise antitumor immunity. A deeper understanding of irAEs and their response to steroids can improve management. Methods Using a multi-omics approach, we investigated blood- and tissue-based correlates of steroid response, focusing on gastro-intestinal irAEs, in the largest cohort to date. Results Here we show clear trends for elevated TC1/TC17 CD8+ T cells and Th1/Th7-associated interleukins before steroid initiation, and persistent (CD8+) T cell activation after initiation of steroids in blood of steroid non-responders. Cross-sectional analysis of colitis tissue suggested lower lymphocyte infiltration within 24 h in steroid responders. Peripheral T cell PD-1 receptor occupancy was unrelated to steroid response. Non-responders’ colitis tissue was enriched with activated CD4+ memory T cells and a pronounced type 1/17 immune response. Conclusions These findings highlight rapid steroid effects on circulating cells and irAE-affected tissue and support that an enhanced type 1/type 17 response may be associated with steroid non-response in irAEs. Validation of these findings in larger cohorts is warranted.
- 18 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 472
Open AccessBlood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
Background High-dose steroids constitute the cornerstone of first-line treatment for immune-related adverse events (irAEs) associated with immune checkpoint inhibitors, but compromise antitumor immunity. A deeper understanding of irAEs and their response to steroids can improve management. Methods Using a multi-omics approach, we investigated blood- and tissue-based correlates of steroid response, focusing on gastro-intestinal irAEs, in the largest cohort to date. Results Here we show clear trends for elevated TC1/TC17 CD8+ T cells and Th1/Th7-associated interleukins before steroid initiation, and persistent (CD8+) T cell activation after initiation of steroids in blood of steroid non-responders. Cross-sectional analysis of colitis tissue suggested lower lymphocyte infiltration within 24 h in steroid responders. Peripheral T cell PD-1 receptor occupancy was unrelated to steroid response. Non-responders’ colitis tissue was enriched with activated CD4+ memory T cells and a pronounced type 1/17 immune response. Conclusions These findings highlight rapid steroid effects on circulating cells and irAE-affected tissue and support that an enhanced type 1/type 17 response may be associated with steroid non-response in irAEs. Validation of these findings in larger cohorts is warranted.